| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d94573ab2c57e8b193f3a22accddf9fe |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-095 |
| filingDate |
2021-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d8520b894df6f2cc2bcb854c3d932d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73bf41d4b29e126f6288d9dcd58fd18a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1be752977debbd5c1a6e9a10686bdbe5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e4a159aa9b31360b7f5939254bbfbab |
| publicationDate |
2022-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022142131-A1 |
| titleOfInvention |
Anti-cancer composition containing auranofin and sulfhydryl compound and use thereof |
| abstract |
Disclosed are an anti-cancer composition containing auranofin and a sulfhydryl compound and the use thereof. The composition contains auranofin and a sulfhydryl compound. By means of using the combination of auranofin and the sulfhydryl compound, the defect of the auranofin being unable to efficiently inhibit the proliferation of cancer cells under normal physiological conditions is overcome. When combined with the sulfhydryl compound, the auranofin can inhibit the growth of tumors well, indicating that the combined use of auranofin and the sulfhydryl compound can be used as an anti-cancer drug combination. In addition, the absorption of auranofin in tumor tissues can be regulated by adjusting the type of the sulfhydryl compound, so that the auranofin has better selectivity in in-vivo cancer resistance. |
| priorityDate |
2020-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |